Qtrypta is our proprietary formulation of zolmitriptan delivered utilizing our System. On February 19, 2021, we received the official Type A meeting minutes from the FDA. Moreover, 80% of these site reactions resolved within 48 hours. Patients however remain dissatisfied with their acute treatments. Therefore, p-values for secondary endpoints should be considered nominal p-values. Several key competitive factors have the potential to affect Qtrypta, if approved. We have one registered trademark to Zosano, "ZOSANO PHARMA", Reg. 87855458 for "TIZOVIAL", Trademark App. The FDA may request additional information rather than accept the NDA for filing. For the twelve months ended December 31, 2020, we incurred a net loss of $33.4 million. Since inception, we have generated no revenues from product sales. Clinical failure can occur at any stage of clinical development. We may never obtain regulatory approval for any of our product candidates. Average review times at the FDA have fluctuated in recent years as a result. We also rely on third parties to manufacture our equipment. Manufacturers of pharmaceutical products often encounter difficulties in production. Collaborations are complex and time-consuming to negotiate and document. We do not carry insurance for all categories of risk that our business may encounter. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. Moreover, the length of the extension could be less than we request. We cannot guarantee that we will not face similar turnover in the future.